Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated

Cancer Research

Volumn 69, Issue 11, 2009, Pages 4800-4809

  Torroella Kouri, Marta ^a,b   Silvera, Risset ^a   Rodriguez, Dayron ^a   Caso, Raul ^a   Shatry, Alwi ^a   Opiela, Shannon ^b   Ilkovitch, Dan ^a   Schwendener, Reto A ^d   Iragavarapu Charyulu, Vijaya ^c   Cardentey, Yoslayma ^b   Strbo, Natasa ^a   Lopez, Diana M ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CD11B ANTIGEN; CD68 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR REL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOLOGY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNE DEFICIENCY; IMMUNOREACTIVITY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3T3 CELLS; ANIMALS; CARCINOMA; CCAAT-ENHANCER-BINDING PROTEINS; CELL DIFFERENTIATION; CELL SEPARATION; CLODRONIC ACID; CYTOKINES; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INFLAMMATION MEDIATORS; MACROPHAGES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NF-KAPPA B; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 66349099293     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3427     Document Type: Article

References (48)

1. Fu YX, Watson G, Jimenez JJ, Wang Y, Lopez DM. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res 1990;50:227-234
2. Kirchner H, Chused TM, Herberman RB, Holden HT, Lavrin DH. Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med 1974;139:1473-1487
3. North RJ. Down-regulation of the antitumor immune response. Adv Cancer Res 1985;45:1-43.
4. Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 2007;101:805-815
5. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-555
6. Ross JA, Auger MJ. The biology of macrophages. In: Burke B, Lewis CE, editors. The macrophage. 2nd ed. Oxford: Oxford University Press; 2002.
7. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-217
8. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545
9. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78
10. Watson GA, Lopez DM. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J Immunol 1995;155:3124-3134
11. Handel-Fernandez ME, Cheng X, Herbert LM, Lopez DM. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-γ production in mammary tumor-bearing mice. J Immunol 1997;158:280-286
12. DiNapoli MR, Calderon CL, Lopez DM. The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med 1996;183:1323-1329
13. Torroella-Kouri M, Ma X, Perry G, et al. Diminished expression of transcription factors nuclear factor κB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice. Cancer Res 2005;65:10578-10584
14. Medina D, DeOme KB. Response of hyperplastic alveolar nodule outgrowth-line D1 to mammary tumor virus, nodule-inducing virus, and prolonged hormonal stimulation acting singly and in combination. J Natl Cancer Inst 1969;42:303-310
15. Calderon C, Huang ZH, Gage DA, Sotomayor EM, Lopez DM. Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidyl serine. J Exp Med 1994;180:945-958
16. Jones M, Komatsu M, Levy RB. Cytotoxically impaired transplant recipients can efficiently resist major histocompatibility complex-matched bone marrow allografts. Biol Blood Marrow Transplant 2000;6:456-464
17. Torroella-Kouri M, Herbert L, Perry G, Lopez DM. Altered IL-12 signaling pathways contribute to the deficient IFN-γ production by T splenocytes from tumor-bearing mice. Cancer Genomics Proteomics 2004;1:345-354
18. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995;3:87-98.
19. Zeisberger SM, Odermatt B, Marty C, Zehnder- Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006;95:272-281
20. Muroi M, Tanamoto K. TRAF6 distinctively mediates MyD88- and IRAK-1-induced activation of NF-κB. J Leukoc Biol 2008;83:702-707
21. Kobayashi K, Hernandez LD, Galan JE, Janeway CA, Jr., Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002;110:191-202.
22. Raingeaud J, Gupta S, Rogers JS, et al. Proinflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995;270:7420-7426
23. Robinson DS, O'Garra A. Further checkpoints in Th1 development. Immunity 2002;16:755-758
24. Cheng F, Wang HW, Cuenca A, et al. A critical role for Stat3signaling in immune tolerance. Immunity 2003;19:425-436
25. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
26. Hickstein DD, Baker DM, Gollahon KA, Back AL. Identification of the promoter of the myelomonocytic leukocyte integrin CD11b. Proc Natl Acad Sci U S A 1992;89:2105-2109
27. Sweet MJ, Hume DA. CSF-1 as a regulator of macrophage activation and immune responses. Arch Immunol Ther Exp (Warsz) 2003;51:169-177
28. Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z, Herbert LM, Grosso JF, Lopez DM. Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. J Immunol 2003;171:4340-4351
29. Torroella-Kouri M, Lopez DM. Mammary tumor derived TGFβ-1 impairs crucial innate immune response in tumor hosts. J Immunol Immunopathol 2003;5:31-38
30. Dohadwala M, Batra RK, Luo J, et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002;277:50828-50833
31. Kalkhoven E, Kwakkenbos-Isbrucker L, Mummery CL, et al. The role of TGF-β production in growth inhibition of breast-tumor cells by progestins. Int J Cancer 1995;61:80-86
32. DiNapoli MR, Calderon CL, Lopez DM. Phosphatidyl serine is involved in the reduced rate of transcription of the inducible nitric oxide synthase gene in macrophages from tumor-bearing mice. J Immunol 1997;158:1810-1817
33. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 2008;180:2011-2017
34. Lin EY, Li JF, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-11246
35. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-5849
36. Murphy TL, Cleveland MG, Kulesza P, Magram J, Murphy KM. Regulation of interleukin 12 p40 expression through an NF-κB half-site. Mol Cell Biol 1995;15:5258-5267
37. Plevy SE, Gemberling JH, Hsu S, Dorner AJ, Smale ST. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol Cell Biol 1997;17:4572-4588
38. Hu WH, Mo XM, Walters WM, Brambilla R, Bethea JR. TNAP, a novel repressor of NF-κB-inducing kinase, suppresses NF-κB activation. J Biol Chem 2004;279:35975-35983
39. Mordmuller B, Krappmann D, Esen M, Wegener E, Scheidereit C. Lymphotoxin and lipopolysaccharide induce NF-κB-p52 generation by a co-translational mechanism. EMBO Rep 2003;4:82-87
40. Biswas SK, Gangi L, Paul S, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation). Blood 2006;107:2112-2122
41. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005;174:4880-4891
42. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-952
43. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007;117:1155-1166
44. Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000;96:3838-3846
45. Mordue DG, Sibley LD. A novel population of Gr-1+-activated macrophages induced during acute toxoplasmosis. J Leukoc Biol 2003;74:1015-1025
46. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001;166:5398-5406
47. Ilkovitch D, Lopez DM. Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec. Blood. Epub 2009 Feb 4.
48. Saccani A, Schioppa T, Porta C, et al. p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006;66:11432-11440